Unlocking the value of oral oncolytics
MISSION
Vaalia's mission is to provide insights on the real-life use of oral oncolytics to enable personalized & targeted intervention and enhance treatment outcomes.
TEAM
Jani Ahonala, founder and CEO of Vaalia, previously founded Noona, a remote patient monitoring platform for cancer care that partnered with leading institutions including Stanford and was acquired by Varian Medical Systems. His experience in healthcare entrepreneurship and pharmaceutical sales informs Vaalia's approach to transforming oncology care.
PROBLEM
Cancer treatment is shifting from traditional infusions to home-based oral oncolytic therapies, but nearly half of patients stop these treatments despite their benefits.
SOLUTION
Vaalia builds a risk prediction model for discontinuation of oral cancer treatment. Their analytics platform is integrated by Physician-aligned pharmacies at the point of care, utilizing data from the care journey, including clinical, and patient information. It identifies high-risk patients, facilitating personalized interventions for improved treatment outcomes.
FOUNDER QUOTE
Successful founders supporting new founders in a way not yet seen in European venture capital. Let us be part of your journey!